Posted by Michael Wonder on 09 Oct 2019
Health Canada approves Evenity for the treatment of osteoporosis in post-menopausal women at high risk for fracture
8 October 2019 - Today Amgen Canada announced that Evenity (romosozumab) is now available in Canada for the treatment of osteoporosis in post-menopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture.
The Canadian approval of Evenity was based on the results of two Phase 3 studies that demonstrated a reduction of new vertebral (spine) fractures and increased bone mineral density.
